Defining the phenotypic spectrum of SLC6A1 mutations

Epilepsia. 2018 Feb;59(2):389-402. doi: 10.1111/epi.13986. Epub 2018 Jan 8.

Abstract

Objective: Pathogenic SLC6A1 variants were recently described in patients with myoclonic atonic epilepsy (MAE) and intellectual disability (ID). We set out to define the phenotypic spectrum in a larger cohort of SCL6A1-mutated patients.

Methods: We collected 24 SLC6A1 probands and 6 affected family members. Four previously published cases were included for further electroclinical description. In total, we reviewed the electroclinical data of 34 subjects.

Results: Cognitive development was impaired in 33/34 (97%) subjects; 28/34 had mild to moderate ID, with language impairment being the most common feature. Epilepsy was diagnosed in 31/34 cases with mean onset at 3.7 years. Cognitive assessment before epilepsy onset was available in 24/31 subjects and was normal in 25% (6/24), and consistent with mild ID in 46% (11/24) or moderate ID in 17% (4/24). Two patients had speech delay only, and 1 had severe ID. After epilepsy onset, cognition deteriorated in 46% (11/24) of cases. The most common seizure types were absence, myoclonic, and atonic seizures. Sixteen cases fulfilled the diagnostic criteria for MAE. Seven further patients had different forms of generalized epilepsy and 2 had focal epilepsy. Twenty of 31 patients became seizure-free, with valproic acid being the most effective drug. There was no clear-cut correlation between seizure control and cognitive outcome. Electroencephalography (EEG) findings were available in 27/31 patients showing irregular bursts of diffuse 2.5-3.5 Hz spikes/polyspikes-and-slow waves in 25/31. Two patients developed an EEG pattern resembling electrical status epilepticus during sleep. Ataxia was observed in 7/34 cases. We describe 7 truncating and 18 missense variants, including 4 recurrent variants (Gly232Val, Ala288Val, Val342Met, and Gly362Arg).

Significance: Most patients carrying pathogenic SLC6A1 variants have an MAE phenotype with language delay and mild/moderate ID before epilepsy onset. However, ID alone or associated with focal epilepsy can also be observed.

Keywords: MAE; SLC6A1; epilepsy; epilepsy genetics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / therapeutic use
  • Ataxia / complications
  • Ataxia / genetics
  • Ataxia / physiopathology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Electroencephalography
  • Epilepsies, Myoclonic / complications
  • Epilepsies, Myoclonic / drug therapy
  • Epilepsies, Myoclonic / genetics
  • Epilepsies, Myoclonic / physiopathology*
  • Epilepsies, Partial / complications
  • Epilepsies, Partial / drug therapy
  • Epilepsies, Partial / genetics
  • Epilepsies, Partial / physiopathology
  • Epilepsy, Generalized / complications
  • Epilepsy, Generalized / drug therapy
  • Epilepsy, Generalized / genetics
  • Epilepsy, Generalized / physiopathology
  • Female
  • GABA Plasma Membrane Transport Proteins / genetics*
  • Genetic Association Studies
  • Humans
  • Intellectual Disability / complications
  • Intellectual Disability / genetics
  • Intellectual Disability / physiopathology*
  • Language Development Disorders / complications
  • Language Development Disorders / genetics
  • Language Development Disorders / physiopathology*
  • Male
  • Mutation
  • Mutation, Missense
  • Neurodevelopmental Disorders / complications
  • Neurodevelopmental Disorders / genetics
  • Phenotype
  • Treatment Outcome
  • Valproic Acid / therapeutic use
  • Young Adult

Substances

  • Anticonvulsants
  • GABA Plasma Membrane Transport Proteins
  • SLC6A1 protein, human
  • Valproic Acid